Findings

What do systematic reviews say?

4,756 questions · 13,493 findings · 1,305 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,594 · 19.2%GRADE not reported 728 · 5.4%Very low 2,868 · 21.3%Low 3,777 · 28%Moderate 2,620 · 19.4%High 906 · 6.7%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

CoronaVac – Sinovac vs placebo

Confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CoronaVac – Sinovac vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 19852 participants
Low

CoronaVac – Sinovac vs placebo

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 19852 participants
Low

CoronaVac – Sinovac vs placebo

All‐cause mortalityh

CoronaVac – Sinovac showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.5 [0.05, 5.52]
2 studies · 22610 participants
Low

BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo

Any adverse eventi

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 46149 participants
Low

CoronaVac – Sinovac vs placebo

Systemic reactogenicity events

CoronaVac – Sinovac showed no clear difference in systemic reactogenicity eventsj compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.19 [1, 1.42]
6 studies · 23966 participants
Low

CoronaVac – Sinovac vs placebo

Any adverse evento

CoronaVac – Sinovac leads to higher any adverse evento compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.09 [1.07, 1.11]
6 studies · 23367 participants
High

CoronaVac – Sinovac vs placebo

Serious adverse eventsr

CoronaVac – Sinovac showed no clear difference in serious adverse eventsr compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.97 [0.62, 1.51]
4 studies · 23139 participants
Low

CoronaVac – Sinovac vs placebo

Local reactogenicity events

CoronaVac – Sinovac leads to higher local reactogenicity eventsj compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.76 [1.69, 1.82]
6 studies · 23962 participants
High

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25449 participants
High

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25480 participants
High

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Severe or critical COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

All‐cause mortalityÂ

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Systemic reactogenicity events

WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in systemic reactogenicity eventse compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.99 [0.95, 1.03]
2 studies · 27029 participants
High

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Any adverse eventh

WIBP‐CorV – Sinopharm‐Wuhan leads to lower any adverse eventh compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.96 [0.93, 0.98]
2 studies · 27029 participants
High

BNT162b2 – Pfizer/BioNTech + Fosun Pharma vs placebo

Serious adverse eventsi

BNT162b2 – Pfizer/BioNTech + Fosun Pharma showed no clear difference in serious adverse eventsi compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.3 [0.55, 3.07]
2 studies · 46107 participants
Low

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Serious adverse eventsi

WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in serious adverse eventsi compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.83 [0.6, 1.15]
2 studies · 27029 participants
Low

WIBP‐CorV – Sinopharm‐Wuhan vs placebo

Local reactogenicity events

WIBP‐CorV – Sinopharm‐Wuhan leads to lower local reactogenicity eventsk compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.88 [0.85, 0.92]
2 studies · 27029 participants
High

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25435 participants
High

BBIBP‐CorV – Sinopharm‐Beijing vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25463 participants
High